| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/16/2006 | WO2006028024A1 9-(1’,5’-dimethyl-1’-vinyl-4’-hexenyl)-4-hydroxy-7h-furo[3,2-g][1]benzopyran-7-one as antibacterial agent |
| 03/16/2006 | WO2006028007A1 Remedy for glomerular diseae |
| 03/16/2006 | WO2006027987A1 Preventive or therapeutic agent for urination disorder |
| 03/16/2006 | WO2006027787A1 Liposomal compositions of glucocorticoid and glucocorticoid derivatives |
| 03/16/2006 | WO2006027786A2 Use of liposomal glucocorticoids for treating inflammatory states |
| 03/16/2006 | WO2006027785A1 Liposomal formulations comprising an amphipathic weak base like tempamine for treatment of neurodegenerative conditions |
| 03/16/2006 | WO2006027694A1 Inhibitors of the hiv integrase enzyme |
| 03/16/2006 | WO2006027692A2 Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives |
| 03/16/2006 | WO2006027691A2 Methods of treating mood disorders using benzisoxazole containing diazabicyclic compounds |
| 03/16/2006 | WO2006027685A2 Glycosylceramide adjuvant for saccharide antigens |
| 03/16/2006 | WO2006027684A1 Therapeutic diphenyl ether ligands |
| 03/16/2006 | WO2006027680A1 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme |
| 03/16/2006 | WO2006027628A2 Naphthalimide derivatives as antiviral agents |
| 03/16/2006 | WO2006027579A2 The treatment of inflammatory disorders and pain |
| 03/16/2006 | WO2006027545A2 Method |
| 03/16/2006 | WO2006027474A2 Novel imidazopyridine derivatives having an affinity with respect to melatonin receptors, method for the preparation thereof and pharmaceutical compositions containing said derivatives |
| 03/16/2006 | WO2006027454A1 Novel derivatives of 3,5-seco-4-norcholestane and use thereof |
| 03/16/2006 | WO2006027397A1 Spiropiperidyl rifamycins for the treatment of microbacterial infections |
| 03/16/2006 | WO2006027378A1 Roflumilast and syk inhibitor combination and methods of use thereof |
| 03/16/2006 | WO2006027377A1 Ciclesonide and syk inhibitor combination and methods of use thereof |
| 03/16/2006 | WO2006027366A1 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity |
| 03/16/2006 | WO2006027365A1 2-substituted-6-trifluoromethyl purine derivatives with adenosine-a3 antagonistic activity |
| 03/16/2006 | WO2006027348A1 Phenylaminopyridines |
| 03/16/2006 | WO2006027347A1 15β-SUBSTITUTED STEROIDS HAVING SELECTIVE ESTROGENIC ACTIVITY |
| 03/16/2006 | WO2006027278A1 Testosterone gels comprising propylene glycol as penetration enhancer |
| 03/16/2006 | WO2006027266A1 Tablets with site time-controlled gastrointestinal release of active ingredient |
| 03/16/2006 | WO2006027252A1 Sigma receptor ligands |
| 03/16/2006 | WO2006027236A1 Alkylidene tetrahydronaphthalene derivatives, method for their production and their use as anti-inflammatory agents |
| 03/16/2006 | WO2006027226A1 Derivatives of aryl(or heteroaryl) azolylcarbinols for the treatment of central neuropathic pain |
| 03/16/2006 | WO2006027223A1 Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion |
| 03/16/2006 | WO2006027221A1 Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction |
| 03/16/2006 | WO2006027211A1 2,4-substituted pyrimidines as cysteine protease inhibitors |
| 03/16/2006 | WO2006027204A1 8-(3-amino-piperidin-1-yl)-7-(but-2-inyl)-xanthines, production thereof and use thereof as medicaments |
| 03/16/2006 | WO2006027142A1 Substituted phenylaminothiazoles and use thereof |
| 03/16/2006 | WO2006027135A1 4-aminomethyl benzamidine derivatives and their use as factor viiia inhibitors |
| 03/16/2006 | WO2006027130A1 Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds |
| 03/16/2006 | WO2006027052A2 (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators |
| 03/16/2006 | WO2006026935A2 Pharmaceutical composition for rectal or vaginal application comprising a platinum complex |
| 03/16/2006 | WO2006026928A1 The vulneraria and the method for producing and using it |
| 03/16/2006 | WO2006026829A1 Stable paste composition of enteric coated acid labile active agent and use thereof |
| 03/16/2006 | WO2006017054A3 Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| 03/16/2006 | WO2006016363A3 Mixture of phytosterol ester(s) and 1, 3-diglyceride(s) for use in the treatment of medical conditions |
| 03/16/2006 | WO2006012502A3 Formulation of insoluble small molecule therapeutics in lipid-based carriers |
| 03/16/2006 | WO2006005609A3 Substituted oxindol derivatives and medicaments containing the same |
| 03/16/2006 | WO2006004759A3 Topical compositions for anti-aging |
| 03/16/2006 | WO2006004574A3 Method for using gamma cyclodextrin to control blood glucose and insulin secretion |
| 03/16/2006 | WO2006002763A3 Substituted tetrahydroisochinolines used in the form of mmp inhibitors, method for the production and use thereof in the form of drags |
| 03/16/2006 | WO2005123680B1 Six-membered heterocycles useful as serine protease inhibitors |
| 03/16/2006 | WO2005123081A3 (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia |
| 03/16/2006 | WO2005121121A3 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 03/16/2006 | WO2005117913A3 Ozonized pharmaceutical composition and method |
| 03/16/2006 | WO2005117911A3 Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin |
| 03/16/2006 | WO2005117893A3 Methods of treating cellular proliferative disease using naphthalimide and parp-1 inhibitors |
| 03/16/2006 | WO2005116047A3 2-substituted 17-imino estrogen compounds for cytoprotection |
| 03/16/2006 | WO2005115546A3 Dimethyl sulfone for the treatment of rosacea |
| 03/16/2006 | WO2005115441A3 Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| 03/16/2006 | WO2005115399A3 Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands |
| 03/16/2006 | WO2005115361A3 Androgen receptor modulators and method of treating disease using the same |
| 03/16/2006 | WO2005113535A3 Pyrazinylmethyl lactam derivatives |
| 03/16/2006 | WO2005113503A3 Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine |
| 03/16/2006 | WO2005113494A3 Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| 03/16/2006 | WO2005113003A3 Method for augmenting b cell depletion |
| 03/16/2006 | WO2005112915A3 Decrease in oxidative stress status through the administration of natural products and pharmaceutical drugs |
| 03/16/2006 | WO2005111605A3 Biomarkers for the prediction and treatment of drug-induced diarrhoea |
| 03/16/2006 | WO2005111195A3 Improved prebiotic |
| 03/16/2006 | WO2005111008A3 Compounds for enzyme inhibition |
| 03/16/2006 | WO2005111002A3 Substituted cycloalkyl derivatives for use in the treatment of respiratory diseases |
| 03/16/2006 | WO2005110442A3 Peritoneal dialysis solution |
| 03/16/2006 | WO2005110421A3 Aerosol formulation for inhalation of beta agonists |
| 03/16/2006 | WO2005110368A8 Intraocular implants of alpha-2 adrenergic receptor agonists and methods for improving vision |
| 03/16/2006 | WO2005110013A3 Methods, compositions, and preparations for delivery of immune response modifiers |
| 03/16/2006 | WO2005107873A3 Glycopyrrolate for treating childhood asthma |
| 03/16/2006 | WO2005107872A3 Treating respiratory diseases with gycopyrrolate and analogues |
| 03/16/2006 | WO2005107711A3 Method and composition for treating rhinitis |
| 03/16/2006 | WO2005106488A3 Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2) |
| 03/16/2006 | WO2005105070A3 Therapeutic antimicrobial compositions and methods |
| 03/16/2006 | WO2005103003A3 Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors |
| 03/16/2006 | WO2005100349A3 Polycyclic pyridines as potassium ion channel modulators |
| 03/16/2006 | WO2005095378A3 Vegetable based dioxanone derivatives, synthesis and uses thereof |
| 03/16/2006 | WO2005094203A3 Sodium ferric gluconate complexes and method of manufacture thereof |
| 03/16/2006 | WO2005091991A3 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
| 03/16/2006 | WO2005089496A3 Methods for the treatment of synucleinopathies |
| 03/16/2006 | WO2005087926A3 Multiple promoter expression cassettes for simultaneous delivery of rnai agents |
| 03/16/2006 | WO2005085443A3 Rnai-based therapeutics for allergic rhinitis and asthma |
| 03/16/2006 | WO2005082942A3 Hydroxyethyl starch |
| 03/16/2006 | WO2005082330A3 Co-precipitated amorphous cefditoren pivoxil and dosage forms comprising the same |
| 03/16/2006 | WO2005082032A3 Treatment of attention disorders |
| 03/16/2006 | WO2005079778A3 Medicaments for treating barrett’s oesophagus |
| 03/16/2006 | WO2005077111A8 Method and preparation for reducing skin hyperpigmentation |
| 03/16/2006 | WO2005077007A3 Methods of diagnosing and treating pre-eclampsia or eclampsia |
| 03/16/2006 | WO2005074632A3 Methods and compositions for treating cancer |
| 03/16/2006 | WO2005070463A3 Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
| 03/16/2006 | WO2005070462A3 Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use |
| 03/16/2006 | WO2005070058A3 Methods and compositions for facilitating metabolic control |
| 03/16/2006 | WO2005063745A3 Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
| 03/16/2006 | WO2005047475A3 Regulation of cell membrane-mediated effects |
| 03/16/2006 | WO2005039486A3 Compounds and compositions as protein kinase inhibitors |
| 03/16/2006 | WO2005037203A3 Methods and reagents for the treatment of immunoinflammatory disorders |
| 03/16/2006 | WO2005030260A8 Bispecific oligonucleotide for the treatment of cns malignancies |
| 03/16/2006 | WO2005023187A3 Inhibitor of cardiac tachyarrhythmias |